Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

ClinicalTrials.gov ID: NCT01513473

Public ClinicalTrials.gov record NCT01513473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in Children and Adolescents 1 to Less Than 18 Years With Type 1 Diabetes Mellitus on a Basal-bolus Regimen With Insulin Aspart as Bolus Insulin, Followed by a 26-week Extension Investigating Long Term Safety (BEGIN™: Young 1)

Study identification

NCT ID
NCT01513473
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

  • insulin aspart Drug
  • insulin degludec Drug
  • insulin detemir Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2012
Primary completion
Jul 29, 2013
Completion
Jul 29, 2013
Last update posted
Jun 12, 2019

2012 – 2013

United States locations

U.S. sites
28
U.S. states
14
U.S. cities
26
Facility City State ZIP Site status
Novo Nordisk Investigational Site Little Rock Arkansas 72202
Novo Nordisk Investigational Site Orange California 92868
Novo Nordisk Investigational Site San Diego California 92123
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site New Haven Connecticut 06511
Novo Nordisk Investigational Site Gainesville Florida 32608
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Maitland Florida 32751
Novo Nordisk Investigational Site Melbourne Florida 32901
Novo Nordisk Investigational Site Tallahassee Florida 32308
Novo Nordisk Investigational Site Atlanta Georgia 30322
Novo Nordisk Investigational Site Atlanta Georgia 30339
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Louisville Kentucky 40202
Novo Nordisk Investigational Site Baltimore Maryland 21201
Novo Nordisk Investigational Site Baltimore Maryland 21229
Novo Nordisk Investigational Site Boston Massachusetts 02215
Novo Nordisk Investigational Site Worcester Massachusetts 01655
Novo Nordisk Investigational Site Buffalo New York 14203
Novo Nordisk Investigational Site Akron Ohio 44308
Novo Nordisk Investigational Site Cincinnati Ohio 45229
Novo Nordisk Investigational Site Hershey Pennsylvania 17033
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224
Novo Nordisk Investigational Site Dallas Texas 75235
Novo Nordisk Investigational Site San Antonio Texas 78207
Novo Nordisk Investigational Site Norfolk Virginia 23507
Novo Nordisk Investigational Site Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01513473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2019 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01513473 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →